News & Updates

GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
08 Mar 2023 byNatalia Reoutova

A population-based retrospective study of Hong Kong patients with type 2 diabetes (T2D) finds that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a lower risk of ischaemic stroke, while use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a lower risk of atrial fibrillation (AF).

GLP-1 RAs vs SGLT2 inhibitors: What are the comparative risks of ischaemic stroke and incident AF?
08 Mar 2023
FDRS variables predict Alzheimer's, dementia in HF, AF patients
FDRS variables predict Alzheimer's, dementia in HF, AF patients
03 Mar 2023
Tirofiban bests aspirin for disabling stroke without large, medium vessel occlusion
Tirofiban bests aspirin for disabling stroke without large, medium vessel occlusion
24 Feb 2023 byAudrey Abella

Findings from the RESCUE BT2 study support the potential of tirofiban to improve neurologic outcomes than aspirin in patients with acute ischaemic stroke without visible large or medium vessel occlusion (LVO or MVO) within 24 hours of last known well or of onset of stroke symptom progression. However, its efficacy was countered by the higher rate of symptomatic intracranial haemorrhage (sICH).

Tirofiban bests aspirin for disabling stroke without large, medium vessel occlusion
24 Feb 2023
Dual antiplatelet therapy after minor, warning stroke: A missed opportunity
Dual antiplatelet therapy after minor, warning stroke: A missed opportunity
24 Feb 2023